Program
deucrictibant
Also written as “Deucrictibant”, “Deucrictibant low dose” and “Deucrictibant high dose”.
Its studies are mostly in Angioedemas, Hereditary, led by Pharvaris Netherlands.
Furthest: phase 3, since Apr 28, 20225 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharvaris Netherlands | 53 open or running | phase 3since Apr 28, 2022 | Sep 7, 2021 | Jun 2027phase 3 · NCT07266805 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2021First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT05047185 · 34 enrolled · United States, Austria, Bulgaria and more
- Apr 28, 2022Phase 3 study in Angioedemas, HereditaryNCT05396105 · 150 planned · United States, Argentina, Australia and more
- Oct 24, 20242 phase 3 studies in Angioedemas, HereditaryNCT06679881, NCT06669754
- Oct 20, 2025Phase 3 study in Angioedemas, HereditaryNCT07266805 · 48 planned · United States, Australia, Austria and more
Ahead
- Jun 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT07266805
- Jun 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT05396105
- Dec 2028Primary completion: phase 3 study in Angioedemas, HereditaryNCT06679881
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07266805Angioedemas, Hereditary · United States, Australia, Austria and more | 3 | Recruiting | Jun 2027 | 48 |
| NCT06679881Angioedemas, Hereditary · United States, Argentina, Australia and more | 3 | By invitation | Dec 2028 | 170 |
| NCT06669754Angioedemas, Hereditary · United States, Argentina, Brazil and more | 3 | Completed | Jul 21, 2026 | 85 |
| NCT05396105Angioedemas, Hereditary · United States, Argentina, Australia and more | 3 | By invitation | Jun 2027 | 150 |
| NCT05047185Angioedemas, Hereditary · United States, Austria, Bulgaria and more | 2 | Terminated | Jun 30, 2025 | 34 |
How it is read
Names in the registry
- “Deucrictibant”, 5 entries
- “deucrictibant”, 2 entries
- “Deucrictibant low dose”, 1 entry
- “Deucrictibant high dose”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.